.Merck trumps revenues assumptions, brings up sales outlook on powerful requirement for top drugs like Keytruda CNBCMerck & Co. (MRK United States) Beats Earnings Estimates as Keytruda Sales Rise BloombergMerck Stock: Pharma Titan Posts Powerful Outcomes, However Expectation Falls Short Financier's Organization DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck defeats revenue as well as sales expectations surrounded by Keytruda asset, but supplies mixed full-year expectation MarketWatch.